<DOC>
	<DOCNO>NCT01007097</DOCNO>
	<brief_summary>The purpose study determine safety efficacy multiple dose TAK-875 , daily ( QD ) , subject Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>Efficacy Safety TAK-875 Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>TAK-875 clinical development treatment type 2 diabetes mellitus human . Non-clinical well Phase I clinical data suggest TAK-875 stimulates insulin secretion elevate blood glucose level . This study conduct study glycemic effect safety TAK-875 compare placebo glimepiride subject type 2 diabetes inadequately control stable dose metformin monotherapy . Subjects participate study require fast 8 hour prior study visit , educate recognition self-management hypoglycemia . In addition , Run-in Period compliance study medication document . Subjects less 80 % than120 % compliant single-blind , placebo regimen run-in period randomize . At conclusion Run-in period , appropriate subject randomize 12 week double-blind treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>Participant meet 1 follow criterion : A historical diagnosis type 2 diabetes mellitus without chronic use antidiabetic therapy within 8 week prior Screening , least 8week documented history diet exercise plan Screening . A historical diagnosis mellitus stable least 1500 mg per day respective ( individually ) maximal tolerate dose metformin monotherapy least 2 month prior Screening . Has glycosylated hemoglobin level Screening 7.5 % 10.0 % , inclusive , metformin great equal 7.5 % le 11 % treat diet exercise alone . Has fast plasma glucose level less 260 mg/dL , Screening . Has fast Cpeptide concentration great equal 0.8 ng/mL Screening . If participant take chronic medication , dose medication must stable ( change dose drug ) least 4 week prior Screening . Participant 's body mass index Screening great equal 23 less equal 45 kg/m2 . Is able willing monitor glucose home glucose monitor consistently record blood glucose concentration . Females childbearing potential sexually active must agree use medically accept mean contraception , neither pregnant lactating Screening throughout duration study 1 month last dose study drug . Compliance singleblind study medication Runin Period least 80 % exceed 120 % base tablet count perform study staff . Has systolic blood pressure great 160 mm Hg diastolic pressure great 100 mm Hg Screening Baseline ( confirm repeat measurement 30 minute initial measurement ) . Has history cancer remission le 5 year prior Screening . A history basal cell carcinoma stage 1 squamous cell carcinoma skin allow . Has creatine phosphokinase level great equal 5 time upper limit normal Screening . Has hemoglobin level less equal 12 g/dL ( 120 gm/L ) men less equal 10 g/dL ( 100 gm/L ) woman Screening . Has alanine aminotransferase aspartate aminotransferase level great equal 2.5 time upper limit normal Screening . Has total bilirubin level great equal 1.5 mg/dL Screening . The subject serum triglyceride concentration great equal 400 mg/dL Screening . Has estimate glomerular filtration rate le equal 60 mL/min use Modification Diet Renal Disease equation Screening . Has abnormal thyroidstimulating hormone level . Has positive test result hepatitis B surface antigen hepatitis C antibody human immunodeficiency virus . Has macroalbuminuria Screening Has history laser treatment proliferative diabetic retinopathy within 6 month prior Screening . Has diabetic gastroparesis investigator 's opinion moderate severe hence may impair absorption study medication . Has coronary angioplasty , coronary stent placement , coronary bypass surgery , myocardial infarction , unstable angina pectoris , clinically significant abnormal electrocardiogram , cerebrovascular accident transient ischemic attack within 6 month prior Screening . Has history hemoglobinopathy may affect determination glycosylated hemoglobin . Received treatment probucol within 1 year randomization . Donated receive blood product within 12 week prior Screening . Received treatment 7 day within 4 week 8 week ( depend medication ) prior Screening . Is insulin treatment . Received investigational drug within 4 week prior Screening . Is hypersensitive TAK875 , excipients glimepiride . Has history drug abuse history alcohol abuse within 2 year prior Screening . Has physical psychiatric disease condition judgment investigator may affect life expectancy may make difficult successfully manage follow subject accord protocol . Is required take intend continue take disallowed medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Probucol Chronically use insulin Chronically use oral parenteral glucocorticoid Chronically use overthecounter prescription weightloss medication and/or Orlistat Niacin 200 mg/day , include niacincontaining product AdvicorÂ® Chronically use peroxisome proliferatoractivated receptor agonist , ezetimibe , oral injectable hypoglycemic agent metformin bileacid bind agent cholestyramine colesevelam Investigational medication Warfarin phenytoin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Diabetes Mellitus , Non Insulin Dependent</keyword>
	<keyword>Diabetes Mellitus , Type II</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>